126 related articles for article (PubMed ID: 12587521)
1. Does long-term use of valproate cause weight gain in prepubertal epileptic children?
Caksen H; Deda G; Berberoğlu M
Int J Neurosci; 2002 Oct; 112(10):1183-9. PubMed ID: 12587521
[TBL] [Abstract][Full Text] [Related]
2. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A
Seizure; 2018 May; 58():90-95. PubMed ID: 29679911
[TBL] [Abstract][Full Text] [Related]
3. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Hamed SA; Fida NM; Hamed EA
Eur J Paediatr Neurol; 2009 May; 13(3):261-8. PubMed ID: 18586538
[TBL] [Abstract][Full Text] [Related]
4. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children.
Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF
Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247
[TBL] [Abstract][Full Text] [Related]
5. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
Sidhu HS; Srinivas R; Sadhotra A
Seizure; 2017 May; 48():15-21. PubMed ID: 28365440
[TBL] [Abstract][Full Text] [Related]
6. Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.
Petty SJ; Kantor S; Lawrence KM; Berkovic SF; Collins M; Hill KD; Makovey J; Sambrook PN; O'Brien TJ; Wark JD
Epilepsia; 2014 Oct; 55(10):1551-7. PubMed ID: 25124647
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate.
Cansu A; Serdaroglu A; Camurdan O; Hırfanoğlu T; Cinaz P
Horm Res Paediatr; 2011; 76(1):65-71. PubMed ID: 21659721
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy.
Grosso S; Luisi S; Mostardini R; Matera M; Barlocco EG; Casarosa E; Balestri P; Petraglia F
Neuroendocrinology; 2011; 93(3):159-64. PubMed ID: 20980729
[TBL] [Abstract][Full Text] [Related]
9. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
Luef G; Abraham I; Hoppichler F; Trinka E; Unterberger I; Bauer G; Lechleitner M
Metabolism; 2002 Oct; 51(10):1274-8. PubMed ID: 12370846
[TBL] [Abstract][Full Text] [Related]
10. The effects of valproate on serum leptin, insulin, and lipid levels in epileptic children.
Kilic H; Demirel A; Uysal S
Pediatr Int; 2021 Nov; 63(11):1351-1356. PubMed ID: 33657654
[TBL] [Abstract][Full Text] [Related]
11. Serum insulin and leptin levels in valproate-associated obesity.
Pylvänen V; Knip M; Pakarinen A; Kotila M; Turkka J; Isojärvi JI
Epilepsia; 2002 May; 43(5):514-7. PubMed ID: 12027912
[TBL] [Abstract][Full Text] [Related]
12. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy.
Kanemura H; Sano F; Maeda Y; Sugita K; Aihara M
Seizure; 2012 Sep; 21(7):496-500. PubMed ID: 22694920
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and endocrine effects of valproic acid chronic treatment.
Belcastro V; D'Egidio C; Striano P; Verrotti A
Epilepsy Res; 2013 Nov; 107(1-2):1-8. PubMed ID: 24076030
[TBL] [Abstract][Full Text] [Related]
14. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy.
Aksoy A; Sönmez FM; Deger O; Hosver I; Karagüzel G
J Pediatr Endocrinol Metab; 2011; 24(9-10):703-8. PubMed ID: 22145460
[TBL] [Abstract][Full Text] [Related]
15. The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy.
Sonmez FM; Zaman D; Aksoy A; Deger O; Aliyazicioglu R; Karaguzel G; Fazlioglu K
Seizure; 2013 Dec; 22(10):856-61. PubMed ID: 23937963
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate.
Aydin K; Serdaroglu A; Okuyaz C; Bideci A; Gucuyener K
J Child Neurol; 2005 Oct; 20(10):848-51. PubMed ID: 16417885
[TBL] [Abstract][Full Text] [Related]
17. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy.
Geda G; Caksen H; Içağasioğlu D
Acta Neurol Belg; 2002 Sep; 102(3):122-6. PubMed ID: 12400250
[TBL] [Abstract][Full Text] [Related]
18. The role of ghrelin in weight gain and growth in epileptic children using valproate.
Gungor S; Yücel G; Akinci A; Tabel Y; Ozerol IH; Yologlu S
J Child Neurol; 2007 Dec; 22(12):1384-8. PubMed ID: 18174556
[TBL] [Abstract][Full Text] [Related]
19. Weight gain in children on oxcarbazepine monotherapy.
Garoufi A; Vartzelis G; Tsentidis C; Attilakos A; Koemtzidou E; Kossiva L; Katsarou E; Soldatou A
Epilepsy Res; 2016 May; 122():110-3. PubMed ID: 27010568
[TBL] [Abstract][Full Text] [Related]
20. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate.
Tokgoz H; Aydin K; Oran B; Kiyici A
Childs Nerv Syst; 2012 Jul; 28(7):1049-53. PubMed ID: 22645062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
